• Dasatinib Monohydrate in Gastric Cancer Assembloids

  2026-09-17

  Dasatinib Monohydrate offers a mechanistically interpretable way to study kinase-dependent drug response across matched gastric tumor organoids and stromal assembloids. This article translates recent patient-derived model findings into practical assay design, controls, and resistance-interpretation strategies.

• 2-NBDG and Sorafenib Resistance in HCC

  2026-09-17

  A translational framework for using fluorescent glucose uptake measurements to complement lipidomics, ferroptosis assays, and organoid models of sorafenib-resistant hepatocellular carcinoma.

• TUNEL Apoptosis Detection Kit: Fish Cell Workflow

  2026-09-16

  Learn how to use a DAB-based TUNEL assay to map DNA fragmentation in oxidative-stress experiments, cultured cells, and tissue sections. This workflow connects the reference study’s miR-183-5p/Keap1-Nrf2 mechanism with practical controls, brightfield imaging, and troubleshooting strategies.

• Anlotinib hydrochloride: Angiogenesis Workflow

  2026-09-16

  Build a mechanism-led angiogenesis workflow around Anlotinib hydrochloride, from receptor phosphorylation to migration and tube formation. The approach combines multi-target pathway validation with practical controls, dose selection, and troubleshooting for reproducible cancer research.

• DRB: A Temporal Probe of RNA Synthesis

  2026-09-15

  5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is more than a transcriptional inhibitor: it is a practical temporal probe for separating RNA synthesis from downstream translation phenotypes. This article connects DRB assay design with new ac4C–lncRNA research while defining the compound’s mechanistic limits.

• Bleomycin Sulfate: From DNA Breaks to Translation

  2026-09-15

  Bleomycin Sulfate is more than a cytotoxic reagent: it is a controllable stress test for DNA damage response, repair capacity, and tissue injury. This article connects its metal-dependent DNA strand-breaking activity with ATM–homologous recombination biology, oncology model design, and pulmonary fibrosis research while outlining practical translational decision points.

• IL-23R as a Senescence-Linked Biomarker of Aging

  2026-09-14

  Carver and colleagues identified IL-23R as a circulating and tissue-associated marker that tracks age-related senescence and responds to senolytic intervention in mice. By comparing pharmacological senolytics with p16-InkAttac-mediated senescent-cell clearance and examining human plasma, the study provides a framework for evaluating systemic senescence biomarkers and possible interorgan signaling factors.

• ABT-199 as a Microglial BCL-2 Probe

  2026-09-14

  ABT-199 (Venetoclax) can do more than trigger apoptosis in hematologic models: it can help test whether BCL-2 is functionally linked to disease-associated microglial states. This article translates aged white-matter findings into a rigorous, limitations-aware assay strategy.

• Annexin V in Metabolic Cancer Cell Death

  2026-09-12

  Discover how Annexin V, a calcium-dependent phosphatidylserine binding protein, can clarify apoptosis assay results in metabolically adaptable cancer cells. This guide connects phosphatidylserine externalization with the CIP2A–PKM2 findings in NSCLC and translates them into practical experimental decisions.

• Veratridine in Sodium Channel Assays

  2026-09-11

  Veratridine provides a controlled way to force persistent sodium-channel activation, making it useful for excitotoxicity studies, channel-blocker screening, and mechanistic neurophysiology. This workflow translates the reference study into practical assay design while highlighting controls, dose selection, and troubleshooting strategies.

• Quizartinib (AC220) Workflows for FLT3 Research

  2026-09-11

  Quizartinib (AC220) combines low-nanomolar FLT3 potency with selectivity that supports cleaner target-engagement studies in AML models. This guide translates that profile into practical phosphorylation, viability, resistance, and xenograft workflows while separating established evidence from assay-development recommendations.

• Asunaprevir (BMS-650032): HCV NS3 Inhibitor

  2026-09-10

  Asunaprevir, also known as BMS-650032, is an orally efficacious HCV NS3/4A protease inhibitor with reported enzymatic IC50 values as low as 1 nM. Its research value lies in HCV RNA replication inhibition, genotype-spanning activity, and hepatotropic exposure, while its product-page evidence does not establish clinical efficacy or activity against unrelated viruses.

• MALAT1–miR-125b–STAT3 Control of PCT in Sepsis

  2026-09-10

  The reference study identifies a MALAT1/miR-125b/STAT3 regulatory axis that increases procalcitonin expression in sepsis-associated inflammatory conditions. By combining patient samples with an LPS-stimulated U937 cell model and several molecular validation assays, the work links a long noncoding RNA mechanism to a clinically used biomarker while also highlighting important limits of PCT specificity.

• Bleomycin Sulfate: Protocols and QC

  2026-09-09

  Bleomycin Sulfate (SKU A8331) provides a practical DNA strand break inducer for chemotherapy-induced DNA damage models, oncology assays, and pulmonary fibrosis research. It is suitable for controlled cell and animal workflows, but should not be selected when ethanol solubility or long-term storage of prepared solutions is required.

• HLY78: Wnt/β-Catenin Pathway Modulator

  2026-09-09

  HLY78 is a ligand-dependent Wnt/β-catenin pathway modulator for dissecting Axin–LRP6 signaling in cell, zebrafish, and fibrosis-related assays. Its value lies in controlled pathway potentiation, allowing researchers to connect LRP6 phosphorylation with embryonic patterning, hematopoietic marker responses, and disease-model readouts without treating a proposed application as established therapy.

8144 records 1/543 page Next 12345 下5页 Last page